Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | MTOR | P42345 | 5/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248047 | 0.84 | GRM2 (0.44) | PIK3CAMTORMAP3K12CNR2ALK | |
| SCHEMBL248108 | 0.79 | PIK3CA (0.49) | PIK3CAMTORCNR2ALKTDO2 | |
| SCHEMBL246004 | 0.79 | PIK3CA (0.45) | PIK3CAMTORMAP3K12BTK | |
| SCHEMBL252272 | 0.77 | ALK (0.47) | CNR2ALK | |
| SCHEMBL249638 | 0.76 | LRRK2 (0.48) | PIK3CAMTORALK | |
| SCHEMBL247853 | 0.75 | ATR (0.48) | PIK3CAMTORAKT1 | |
| SCHEMBL246130 | 0.75 | LRRK2 (0.50) | PIK3CAMTORCNR2 | |
| SCHEMBL3410821 | 0.75 | CNR2 (0.49) | CNR2TDO2 | |
| SCHEMBL246958 | 0.75 | ALK (0.49) | PIK3CAMTORKITCNR2ALK | |
| SCHEMBL247209 | 0.75 | LRRK2 (0.43) | PIK3CAMTORMAP3K12CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CA 28/4885MTOR 314/4885KIT 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.